Sign Out
Exemestane is indicated for the adjuvant treatment of post-menopausal women with estrogen receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to Exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy.
Exemestane is indicated for the second-line treatment of advanced breast cancer (ABC) in women with natural or induced post-menopausal status whose disease has progressed following anti-estrogen therapy alone.
Exemestane is also indicated for the third-line treatment of post-menopausal woman with ABC whose disease has progressed following multiple hormonal therapies. Efficacy has not been demonstrated in patients with estrogen receptor negative status.
Continue with Google